Gyre Therapeutics Inc. (GYRE) - Total Assets
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) holds total assets worth $159.38 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See GYRE book value for net asset value and shareholders' equity analysis.
Gyre Therapeutics Inc. - Total Assets Trend (2001–2024)
This chart illustrates how Gyre Therapeutics Inc.'s total assets have evolved over time, based on quarterly financial data.
Gyre Therapeutics Inc. - Asset Composition Analysis
Current Asset Composition (December 2024)
Gyre Therapeutics Inc.'s total assets of $159.38 Million consist of 51.7% current assets and 48.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.4% |
| Accounts Receivable | $29.15 Million | 23.3% |
| Inventory | $6.34 Million | 5.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $1.71 Million | 1.4% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2001–2024)
This chart illustrates how Gyre Therapeutics Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Gyre Therapeutics Inc. market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Gyre Therapeutics Inc.'s current assets represent 51.7% of total assets in 2024, an increase from 0.0% in 2001.
- Cash Position: Cash and equivalents constituted 9.4% of total assets in 2024, up from 0.0% in 2001.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 1.0% of total assets, an increase from 0.0% in 2001.
- Asset Diversification: The largest asset category is accounts receivable at 23.3% of total assets.
Gyre Therapeutics Inc. Competitors by Total Assets
Key competitors of Gyre Therapeutics Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Gyre Therapeutics Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.19 | 3.72 | 5.03 |
| Quick Ratio | 5.64 | 3.29 | 5.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $82.66 Million | $40.09 Million | $71.71 Million |
Gyre Therapeutics Inc. - Advanced Valuation Insights
This section examines the relationship between Gyre Therapeutics Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.12 |
| Latest Market Cap to Assets Ratio | 5.80 |
| Asset Growth Rate (YoY) | 7.6% |
| Total Assets | $125.41 Million |
| Market Capitalization | $727.32 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Gyre Therapeutics Inc.'s assets at a significant premium (5.80x), suggesting investors see substantial growth potential or unique competitive advantages.
Positive Asset Growth: Gyre Therapeutics Inc.'s assets grew by 7.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Gyre Therapeutics Inc. (2001–2024)
The table below shows the annual total assets of Gyre Therapeutics Inc. from 2001 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $125.41 Million | +7.61% |
| 2023-12-31 | $116.54 Million | +37.50% |
| 2022-12-31 | $84.75 Million | +52.26% |
| 2021-12-31 | $55.66 Million | -41.31% |
| 2020-12-31 | $94.85 Million | -3.76% |
| 2019-12-31 | $98.55 Million | -21.11% |
| 2018-12-31 | $124.92 Million | +216.15% |
| 2017-12-31 | $39.51 Million | +3.74% |
| 2016-12-31 | $38.09 Million | -45.21% |
| 2015-12-31 | $69.52 Million | -37.93% |
| 2014-12-31 | $112.00 Million | -23.22% |
| 2013-12-31 | $145.87 Million | -23.05% |
| 2012-12-31 | $189.58 Million | -26.56% |
| 2011-12-31 | $258.13 Million | -1.77% |
| 2010-12-31 | $262.79 Million | -17.72% |
| 2009-12-31 | $319.38 Million | +224.07% |
| 2008-12-31 | $98.55 Million | -0.42% |
| 2007-12-31 | $98.96 Million | +21.63% |
| 2006-12-31 | $81.37 Million | +190.59% |
| 2005-12-31 | $28.00 Million | -51.89% |
| 2004-12-31 | $58.20 Million | +22.82% |
| 2003-12-31 | $47.39 Million | -12.85% |
| 2002-12-31 | $54.38 Million | +122.90% |
| 2001-12-31 | $24.40 Million | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more